SCLC
FDA approves Jazz Pharmaceuticals’ Modeyso as first drug for ultra-rare brain cancer
H3 K27M-mutant diffuse midline glioma affects an estimated 2,000 people in the US every year
EC approves Jazz Pharmaceuticals’ Ziihera for advanced biliary tract cancer
Approximately 26% of biliary tract cancer patients globally have HER2-positive disease
Roche/Jazz share positive phase 3 results for lung cancer combination therapy
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
Jazz shares positive results for Zepzelca combination in phase 3 lung cancer study
Approximately 30,000 new cases of small cell lung cancer are reported in the US every year
PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19
Early study results published in peer-reviewed journal Science
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
Drug combination failed to improve overall survival rate
Redx Pharma links up with Jazz Pharmaceuticals to develop targeted cancer drugs
Collaboration will focus on two cancer targets on the Ras/Raf/MAP kinase pathway
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
Solidifies immunotherapy drug's dominance in the setting
AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC
Will go head-to-head with rival Roche's Tecentriq if approved
Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy
The latest from pharma, biotech and healthcare
FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer
Becomes the first checkpoint inhibitor for this indication